Search research articles
Contact Us
Filters
Showing results (141-150 of 154) with videos related to
Page
of 16
Sort By:
Frontiers in Immunology
|
October 28, 2022
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Cell Proliferation
|
November 29, 2018
MiR-326/Sp1/KLF3: A novel regulatory axis in lung cancer progression
Rong Wang, Jiali Xu, Jing Xu, et al.
Translational Oncology
|
April 14, 2019
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Journal for Immunotherapy of Cancer
|
February 9, 2023
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
Xiaofeng Chen, Xiang Xu, Danping Wang, et al.
Nature Communications
|
July 20, 2019
Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases
Jing Sun, Cheng Wang, Yi Zhang, et al.
Signal Transduction and Targeted Therapy
|
March 14, 2025
PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial
Yakun Wang, Jialin Lu, Xiaoyi Chong, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|
July 11, 2026
Neuroprotection and prevention of oxaliplatin-induced neuropathy with Huangqi Guizhi Wuwu Decoction: a 12-center randomized, double-blind trial with mechanistic validation
Xiaohe Sun, Yan Fang, Xueying Yang, et al.
Journal for Immunotherapy of Cancer
|
November 11, 2020
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
Xiaofeng Chen, Xiaofeng Wu, Hao Wu, et al.
Cancer Communications (London, England)
|
October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials
Jian Li, Ting Deng, Yanhong Gu, et al.
Analytical Chemistry
|
July 16, 2025
Proteomic Profiling of Urinary Large Extracellular Vesicles for the Diagnosis of Prostate Cancer
Yu-Ping Fan, Yu-Ting Zhang, Guiyuan Zhang, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 154) with videos related to
Sort By:
Page
of 16
Frontiers in Immunology
|
October 28, 2022
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Cell Proliferation
|
November 29, 2018
MiR-326/Sp1/KLF3: A novel regulatory axis in lung cancer progression
Rong Wang, Jiali Xu, Jing Xu, et al.
Translational Oncology
|
April 14, 2019
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Journal for Immunotherapy of Cancer
|
February 9, 2023
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
Xiaofeng Chen, Xiang Xu, Danping Wang, et al.
Nature Communications
|
July 20, 2019
Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases
Jing Sun, Cheng Wang, Yi Zhang, et al.
Signal Transduction and Targeted Therapy
|
March 14, 2025
PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial
Yakun Wang, Jialin Lu, Xiaoyi Chong, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|
July 11, 2026
Neuroprotection and prevention of oxaliplatin-induced neuropathy with Huangqi Guizhi Wuwu Decoction: a 12-center randomized, double-blind trial with mechanistic validation
Xiaohe Sun, Yan Fang, Xueying Yang, et al.
Journal for Immunotherapy of Cancer
|
November 11, 2020
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
Xiaofeng Chen, Xiaofeng Wu, Hao Wu, et al.
Cancer Communications (London, England)
|
October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials
Jian Li, Ting Deng, Yanhong Gu, et al.
Analytical Chemistry
|
July 16, 2025
Proteomic Profiling of Urinary Large Extracellular Vesicles for the Diagnosis of Prostate Cancer
Yu-Ping Fan, Yu-Ting Zhang, Guiyuan Zhang, et al.
Page
of 16